ClinicalTrials.gov
public full text
Public Domain
The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk
Cardiovascular risk has been shown to increase with increasing blood pressure values. As a consequence, it results mandatory to achieve lower blood pressure goals in all hypertensive patients, taking into account that all drugs always have some side effects that can be very dangerous and/or uncomfortable for the patients leading to a reduced compliance. Thus, pharmacological treatment should be delayed until it results really necessary. The availability of natural substances with a therapeutic action has modified this scenario because of their reduced potential to cause undesirable effects (compared with drugs). In order to choose among various nutraceuticals (natural foods compounds with health benefits, including the prevention and/or treatment of diseases), preference should be given to those * produced according to the same Good Manufacturing Practice used for drugs, to be sure that the finished product has a standard, reproducible composition * for which efficacy and safety in the recommended indications are supported by clinical trials. An example of a product with these characteristics is Armolipid Plus, a combination of nutraceuticals with a demonstrated anti-dyslipidaemic effect. Recently, a large clinical intervention study showed evidence that treatment with Armolipid Plus leads to a significant decrease in the overall cardiovascular risk, measured using the Framingham Risk Score. Progress in Research and Development in this field has led to a new patented and registered combination of nutraceuticals: Armolipid Prev, containing orthosiphon and CoQ10, with antihypertensive activity, berberine, red yeast, policosanol and orthosiphon with antidyslipidaemic effect and folic acid, reducing plasma homocysteine levels. In addition to the established anti-dyslipidaemic activity of Armolipid plus, Armolipid Prev has a significant antihypertensive effect, which is beneficial in all those patients with high blood pressure values without a defined indication to
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Image 3_Serum free eicosapentaenoic acid-to-arachidonic acid ratio and long-term risk of major adverse cardiovascular events in patients with coronary artery disease.tiff#1120080
- Image 1_Serum free eicosapentaenoic acid-to-arachidonic acid ratio and long-term risk of major adverse cardiovascular events in patients with coronary artery disease.tiff#1120082
- Image 2_Serum free eicosapentaenoic acid-to-arachidonic acid ratio and long-term risk of major adverse cardiovascular events in patients with coronary artery disease.tiff#1120081
- Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events#1163008
- Data Sheet 1_Serum free eicosapentaenoic acid-to-arachidonic acid ratio and long-term risk of major adverse cardiovascular events in patients with coronary artery disease.docx#1120079
Record · ID 1419861
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive